Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.
A total of 590 clinical isolates consisting of 33 species of both gram-positive and gram-negative anaerobes were collected from nine centers in the Chicago area in 1998-1999. The largest number of isolates (330 isolates, 56%) belonged to the Bacteroides group. Isolates were tested by agar dilution against garenoxacin (BMS-284756, T-3811 ME), trovafloxacin, moxifloxacin, clindamycin, imipenem, piperacillin-tazobactam, and cefoxitin. All but one species (2% of Bacteroides vulgatus isolates) were fully susceptible to piperacillin-tazobactam and imipenem. A number of species were resistant to clindamycin. Among the fluoroquinolones, garenoxacin and trovafloxacin had an MIC at which 90% of the isolates tested were inhibited of <4 micro g/ml for all but two species (Fusobacterium mortiferum/varium and Peptostreptococcus anaerobius).
Hecht
David W
DW
Hines VA Hospital, Hines, Illinois, USA. dhecht@lumc.edu
Osmolski
J R
JR
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001424:Bacterial Infections / Q000453:epidemiology / Q000382:microbiology*; D002641:Chicago / Q000453:epidemiology; D003470:Culture Media; D024841:Fluoroquinolones; D007211:Indoles / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D003470:Culture Media; D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; C419689:garenoxacin